(Q40859206)

24 September 2017

1 reference

title

Biomodulation of Fluorouracil in colorectal cancer (English)

1 reference

24 September 2017

1 reference

1 reference

B Ardalan

1

1 reference

24 September 2017

R Luis

series ordinal

2

1 reference

24 September 2017

M Jaime

series ordinal

3

1 reference

24 September 2017

D Franceschi

series ordinal

4

1 reference

24 September 2017

publication date

1 January 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

16

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

237-251

1 reference

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Role of chemotherapy in the treatment of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug Synergism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Biochemical pharmacology of the lipophilic antifolate, trimetrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A Phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Inhibition of cell division by interferons. The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

Induction and kinetics of natural killer cells in humans following interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909809039773

10.3109/07357909809039773

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference